CytomX Therapeutics Q4 2022 Earnings Report

CytomX Therapeutics EPS Results

• Actual EPS: -$0.42
• Consensus EPS: -$0.21
• Beat/Miss: Missed by -$0.21
• One Year Ago EPS: N/A

CytomX Therapeutics Revenue Results

• Actual Revenue: $0.95 million
• Expected Revenue: $17.71 million
• Beat/Miss: Missed by -$16.76 million
• YoY Revenue Growth: N/A

CytomX Therapeutics Announcement Details

• Quarter: Q4 2022
• Date: 3/27/2023
• Time: N/A

CytomX Therapeutics (NASDAQ:CTMX), an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.